172 related articles for article (PubMed ID: 33355217)
1. Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.
Luo P; Zheng JL; Liu Y; Qiu L; Liu XL; Xue HY; Liu D; Li J
Clin Med (Lond); 2021 Jan; 21(1):e80-e83. PubMed ID: 33355217
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
4. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
5. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
Giacomelli A; Pagani G; Ridolfo AL; Oreni L; Conti F; Pezzati L; Bradanini L; Casalini G; Bassoli C; Morena V; Passerini S; Rizzardini G; Cogliati C; Ceriani E; Colombo R; Rusconi S; Gervasoni C; Cattaneo D; Antinori S; Galli M
J Med Virol; 2021 Mar; 93(3):1421-1427. PubMed ID: 32776534
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.
Gao G; Wang A; Wang S; Qian F; Chen M; Yu F; Zhang J; Wang X; Ma X; Zhao T; Zhang F; Chen Z
J Acquir Immune Defic Syndr; 2020 Oct; 85(2):239-243. PubMed ID: 32740371
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
Qu J; Li GH; Wang JJ; He GF; Huang JJ; Chen Y; Qu Q; Chen XY; Lu Q
Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):203-210. PubMed ID: 33090501
[TBL] [Abstract][Full Text] [Related]
8. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
[TBL] [Abstract][Full Text] [Related]
9. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
Karolyi M; Pawelka E; Mader T; Omid S; Kelani H; Ely S; Jilma B; Baumgartner S; Laferl H; Ott C; Traugott M; Turner M; Seitz T; Wenisch C; Zoufaly A
Wien Klin Wochenschr; 2021 Apr; 133(7-8):284-291. PubMed ID: 32776298
[TBL] [Abstract][Full Text] [Related]
11. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
Brandariz-Nuñez D; Correas-Sanahuja M; Guarc E; Picón R; García B; Gil R
Med Clin (Barc); 2020 Oct; 155(7):281-287. PubMed ID: 32718719
[TBL] [Abstract][Full Text] [Related]
12. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
[TBL] [Abstract][Full Text] [Related]
13. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
[TBL] [Abstract][Full Text] [Related]
16. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
[TBL] [Abstract][Full Text] [Related]
17. Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
Liu J; Du C; Pu L; Xiang P; Xiong H; Xie W; Chen Z; Li A
BMC Infect Dis; 2021 Aug; 21(1):885. PubMed ID: 34461841
[TBL] [Abstract][Full Text] [Related]
18. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial.
Tan DHS; Chan AK; Jüni P; Tomlinson G; Daneman N; Walmsley S; Muller M; Fowler R; Murthy S; Press N; Cooper C; Lee T; Mazzulli T; McGeer A
Trials; 2021 Mar; 22(1):224. PubMed ID: 33752741
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K
Expert Rev Anti Infect Ther; 2021 Jun; 19(6):679-687. PubMed ID: 33187459
[No Abstract] [Full Text] [Related]
20. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.
Ye XT; Luo YL; Xia SC; Sun QF; Ding JG; Zhou Y; Chen W; Wang XF; Zhang WW; Du WJ; Ruan ZW; Hong L
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3390-3396. PubMed ID: 32271456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
